AstraZeneca (NASDAQ:AZN) has started a worldwide withdrawal of the COVID-19 vaccine, which it co-developed with the University of Oxford, citing a surplus of vaccines updated for the latest variants.
It's hard to escape the conclusion that having been second best during the pandemic era, Novavax may run into the same problems in a commercial COVID vaccine market. The company will update on its ...
PharmaTher received the new date after it “promptly completed the necessary tests and responses” to address the FDA’s concerns ... Veklury was the first COVID treatment to win backing ...
With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. The shot is no longer being manufactured or ...
Oct. 2, 2023 — In September 2022, new bivalent COVID-19 boosters became available in the United States, but less than 20% of the eligible population ultimately received one. A new study ...
The concurrent administration of bivalent mRNA COVID-19 boosters and influenza vaccines should be considered as a strategy to potentiate neutralizing antibody responses against SARS-CoV-2. Concurrent ...
The concurrent administration of bivalent mRNA COVID-19 boosters and influenza vaccines should be considered as a strategy to potentiate neutralizing antibody responses against SARS-CoV-2. Concurrent ...
Most hospitalized patients had multiple chronic conditions (90.3%; 95% CI, 87.2% to 92.8%), and only 23.5% (95% CI, 19.5% to 27.7%) had received the recommended bivalent (two-strain) vaccine. A total ...
Unlimited access to premium stories for as little as $12.95 /mo.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results